Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Projected economic burden of pancreatic cancer in Sweden in 2030

Draus, Tomasz LU orcid ; Ansari, Daniel LU ; Wikström, Filip ; Persson, Ulf LU and Andersson, Roland LU (2021) In Acta Oncologica 60(7). p.866-871
Abstract

Background: Pancreatic cancer is predicted to become the second most common cause of cancer-related death by 2030. The objective of this study was to estimate the economic burden of pancreatic cancer for the years 2018 and 2030 based on changing demographics and incidence rates in Sweden. Method: The incidence of pancreatic cancer in Sweden and additional relevant data were obtained from official statistics. A linear regression model and the mean incidence rates 2008–2018 were applied to calculate the incidence in 2030. An economic model based on the human capital method was created to calculate the indirect cost of pancreatic cancer in 2018 and 2030. Costs associated with surgery, radiology, oncology, and palliative care constituted... (More)

Background: Pancreatic cancer is predicted to become the second most common cause of cancer-related death by 2030. The objective of this study was to estimate the economic burden of pancreatic cancer for the years 2018 and 2030 based on changing demographics and incidence rates in Sweden. Method: The incidence of pancreatic cancer in Sweden and additional relevant data were obtained from official statistics. A linear regression model and the mean incidence rates 2008–2018 were applied to calculate the incidence in 2030. An economic model based on the human capital method was created to calculate the indirect cost of pancreatic cancer in 2018 and 2030. Costs associated with surgery, radiology, oncology, and palliative care constituted the direct costs. A sensitivity analysis was performed. Results: The incidence of pancreatic cancer in Sweden in the year 2018 was 1352 patients and projected to between 1554 (+15%) and 1736 (+28%) in 2030. The total cost was calculated to €125 million in 2018 and between €210 million (+68%) and €225 million (+80%) in 2030. The indirect cost in the ≤65-year-old group was €328,344 in 2018 and between €380,738 and €382,109 per individual in 2030. Conclusions: The economic burden of pancreatic cancer is expected to increase in Sweden by 2030 due to the increasing incidence of the disease and changing demographics. Pancreatic cancer is a growing health care problem in urgent need of advancements in prevention, early detection, treatment, and control of the disease.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
2030, economic burden, Pancreatic cancer, projections, Sweden
in
Acta Oncologica
volume
60
issue
7
pages
866 - 871
publisher
Taylor & Francis
external identifiers
  • scopus:85102960869
  • pmid:33729903
ISSN
0284-186X
DOI
10.1080/0284186X.2021.1892821
project
Reducing the Burden of Pancreatic Cancer
language
English
LU publication?
yes
id
40619dc0-69f3-435e-805e-3e91a2eec56c
date added to LUP
2021-03-31 12:44:53
date last changed
2024-04-20 03:56:03
@article{40619dc0-69f3-435e-805e-3e91a2eec56c,
  abstract     = {{<p>Background: Pancreatic cancer is predicted to become the second most common cause of cancer-related death by 2030. The objective of this study was to estimate the economic burden of pancreatic cancer for the years 2018 and 2030 based on changing demographics and incidence rates in Sweden. Method: The incidence of pancreatic cancer in Sweden and additional relevant data were obtained from official statistics. A linear regression model and the mean incidence rates 2008–2018 were applied to calculate the incidence in 2030. An economic model based on the human capital method was created to calculate the indirect cost of pancreatic cancer in 2018 and 2030. Costs associated with surgery, radiology, oncology, and palliative care constituted the direct costs. A sensitivity analysis was performed. Results: The incidence of pancreatic cancer in Sweden in the year 2018 was 1352 patients and projected to between 1554 (+15%) and 1736 (+28%) in 2030. The total cost was calculated to €125 million in 2018 and between €210 million (+68%) and €225 million (+80%) in 2030. The indirect cost in the ≤65-year-old group was €328,344 in 2018 and between €380,738 and €382,109 per individual in 2030. Conclusions: The economic burden of pancreatic cancer is expected to increase in Sweden by 2030 due to the increasing incidence of the disease and changing demographics. Pancreatic cancer is a growing health care problem in urgent need of advancements in prevention, early detection, treatment, and control of the disease.</p>}},
  author       = {{Draus, Tomasz and Ansari, Daniel and Wikström, Filip and Persson, Ulf and Andersson, Roland}},
  issn         = {{0284-186X}},
  keywords     = {{2030; economic burden; Pancreatic cancer; projections; Sweden}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{866--871}},
  publisher    = {{Taylor & Francis}},
  series       = {{Acta Oncologica}},
  title        = {{Projected economic burden of pancreatic cancer in Sweden in 2030}},
  url          = {{http://dx.doi.org/10.1080/0284186X.2021.1892821}},
  doi          = {{10.1080/0284186X.2021.1892821}},
  volume       = {{60}},
  year         = {{2021}},
}